Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05159492
Other study ID # CHUBX 2021/03
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date December 27, 2021
Est. completion date February 1, 2025

Study information

Verified date January 2024
Source University Hospital, Bordeaux
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

BEAT AF is a randomized controlled trial aiming to demonstrate that pulsed field energy is faster, more effective and safer (tissue selectivity) than RF for paroxysmal AF ablation


Description:

Atrial fibrillation (AF), the most common arrhythmia, accounts for 1/3rd of Cardiovascular expenses, with over 10 millions affected in Europe. In addition to significant impact on quality of life, AF exposes patients to stroke, heart failure, dementia and death. AF is the most commonly ablated arrhythmia. The Pulmonary Vein Isolation (PVI) is the cornerstone of AF ablation, preventing recurrences, especially in patients with paroxysmal AF. Catheter ablation of AF uses either radiofrequency (RF) or cryothermal (cryo) energy. Common to these thermal energy sources is their reliance on time-dependent conductive heating/cooling and the fact that these modalities ablate all tissue types indiscriminately. The ablation procedure remains long, requires skills and expertise, and has a limited success rate, mostly because of non-durable lesions after PVI implying frequent redo procedures. And these energies are associated with rare but severe complications due to their thermal nature. The goal of BEAT AF is to disrupt AF ablation by achieving durable PVI with permanent, coalescent and transmural ablation lesions using Pulsed Electric Field (PEF) energy. PEF is non-thermal and creates nanoscale pores in cell membranes. Cardiac cells are highly sensitive to PEF unlike phrenic and oesophageal cells. BEAT AF aims to demonstrate that PEF ablation is faster, more effective and safer (tissue selectivity) than RF ablation to treat paroxysmal AF. For this purpose, a randomized clinical trial will be conducted to provide first comparative evidence of the superiority of PEF over RF on the rate of 1-year recurrence for paroxysmal AF. The BEAT AF consortium gathers 9 European renowned clinical centres (France, Czech Republic, Germany, Austria, Belgium) to contribute to decrease the huge burden of AF.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 292
Est. completion date February 1, 2025
Est. primary completion date February 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients with drug-resistant symptomatic PAF meeting all the following criteria: 1. Paroxysmal: AF that terminates spontaneously or with intervention within 7 days of onset. 2. Frequency: i. Physician documentation of recurrent PAF (two or more episodes) within 6 months, AND ii. At least one (1) documented episode by a recording such as ECG, Event Monitor, Holter monitor or telemetry strip within 12 months of enrolment. c. Drug failed: Failed AAD treatment, meaning therapeutic failure of at least one (1) AAD (Class I to IV) for efficacy and / or intolerance. 2. Patients who are = 18 and = 75 years of age on the day of enrollment. 3. Patient who are willing and capable of: 1. Providing informed consent to undergo study procedures AND 2. Participating in all examinations and follow-up visits and tests associated with this clinical study. 3. Patient having a smart phone compatible with the Event Monitor device. 4. Effective contraception for women of childbearing potential. 5. Effective oral anticoagulation >3 weeks prior to planned ablation procedure 6. Patient affiliated to or beneficiary of national health security scheme for French participants. Exclusion Criteria: - 1. AF that is any of the following: 1. Persistent (both early and longstanding) by diagnosis or continuous duration > 7 days 2. Secondary to electrolyte imbalance, thyroid disease, alcohol or other reversible / non-cardiac causes 2. Any of the following atrial conditions: 1. Left atrial anteroposterior diameter = 5.5 cm (by MRI, CT or TTE) 2. Any prior atrial endocardial or epicardial ablation procedure, other than right sided cavotricuspid isthmus ablation or for right sided SVT 3. Any prior atrial surgery 4. Intra-atrial septal patch or interatrial shunt 5. Atrial myxoma 6. Current LA thrombus 7. LA appendage closure, device or occlusion, past or anticipated 8. Any PV abnormality, stenosis or stenting (common and middle PVs are admissible) 3. At any time, one (1) or more of the following cardiovascular procedures, implants or conditions: a. Sustained ventricular tachycardia or any ventricular fibrillation b. Hemodynamically significant valvular disease: i. Valvular disease that is symptomatic ii. Valvular disease causing or exacerbating congestive heart failure iii. Aortic stenosis: if already characterized, valve area < 1.5cm or gradient > 20 mm Hg iv. Mitral stenosis: if already characterized, valve area < 1.5cm or gradient > 5 mm Hg v. Aortic or mitral regurgitation associated with abnormal LV function or hemodynamic measurements c. Hypertrophic cardiomyopathy d. Any prosthetic heart valve, ring or repair including balloon aortic valvuloplasty e. Pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy devices f. Any inferior vena cava (IVC) filter, known inability to obtain vascular access or other contraindication to femoral access g. History of rheumatic fever h. History of congenital heart disease with any residual anatomic or conduction abnormality 4. Any of the following procedures, implants or conditions: a. At baseline: i. New York Heart Association (NYHA) Class III/IV ii. Left ventricular ejection fraction (LVEF) < 40% iii. Symptomatic hypotension iv. Uncontrolled hypertension (SBP > 160 mmHg or DBP > 95 mmHg on two BP measurements at baseline assessment) v. Symptomatic resting bradycardia vi. Implantable loop recorder or insertable cardiac monitor, b. Within the 3 months preceding the Consent Date: i. Myocardial infarction ii. Unstable angina iii. Percutaneous coronary intervention iv. Heart failure hospitalization v. Pericarditis or symptomatic pericardial effusion vi. Gastrointestinal bleeding c. Within the 6 months preceding the Consent Date: i. Heart surgery ii. Stroke, TIA or intracranial bleeding iii. Any thromboembolic event iv. Carotid stenting or endarterectomy 5. Diagnosed disorder of blood clotting or bleeding diathesis 6. Contraindication to, or unwillingness to use, systemic anticoagulation 7. Contraindication to both CT and MRI 8. Sensitivity to contrast media not controllable by premedication 9. Women of childbearing potential who are pregnant, lactating, not using medical birth control or who are planning to become pregnant during the anticipated study period 10. Medical conditions that would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation, including but not limited to: 1. Body Mass Index (BMI) > 40.0 2. Solid organ or hematologic transplant, or currently being evaluated for an organ transplant 3. Severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen 4. Renal insufficiency with an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2, or any history of renal dialysis or renal transplant 5. Active malignancy or history of treated malignancy within 24 months of enrollment (other than cutaneous basal cell or squamous cell carcinoma) 6. Clinically significant gastrointestinal problems involving the esophagus or stomach including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration 7. Active systemic infection 8. COVID-19 disease 9. Current confirmed, active COVID-19 disease ii. Current positive test for SARS-CoV-2 iii. Confirmed COVID-19 disease not clinically resolved at least 3 months prior to the Consent Date. i. Other uncontrolled medical conditions that may modify device effect or increase risk, including uncontrolled diabetes mellitus (HgbA1c > 8.0% if test result already obtained), untreated obstructive sleep apnea or active alcohol abuse j. Predicted life expectancy less than one (1) year 11. Clinically significant psychological condition that in the Investigator's opinion would prohibit the subject's ability to meet the protocol requirements/ Patient under legal protection 12. Current or anticipated enrollment in any other clinical study. 13. Employees / family members of: 1. FARAPULSE or any of its affiliates or contractors 2. The Investigator, sub-Investigators, or their medical office or practice, or healthcare organizations at which study procedures may be performed.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
PVI using PEF
PVI using PEF
PVI using CFRF
PVI using CFRF

Locations

Country Name City State
Austria Medical University of Graz Graz
Belgium AZ Sint-Jan Brugge-Oostende Bruges
Czechia Homolka Hospital Prague
Czechia Institute for Clinical and Experimental Medicine Prague
France CHU Bordeaux Pessac
France CHU Toulouse Toulouse
France Clinique Pasteur, Toulouse Toulouse
Germany Cardiovascular Center Bad Neustadt Bad Neustadt an der Saale
Germany Deutsches Herzzentrum München Munich

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Bordeaux Funding: European Commission (H2020)

Countries where clinical trial is conducted

Austria,  Belgium,  Czechia,  France,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary proportion of subjects experiencing 1-year single-procedure clinical success The Primary Efficacy Endpoint is the proportion of subjects experiencing 1-year single-procedure clinical success, defined as (2017 HRS consensus statement):
Successful index AF ablation
Absence of atrial arrhythmia recurrence on any type of recording (= 30 sec by TTM (event monitor), Holters, 12-lead ECGs, rhythm strip or other diagnostic ECG documentation),
Absence of use of class I or III AAD (except for non-atrial arrhythmia)
Absence of redo ablation (except for typical flutter), in the 12 months following the index ablation procedure (including a blanking period of 60 days following the index ablation procedure).
1 year
Secondary proportion of subjects with 1-year multiple-procedures success proportion of subjects with 1-year multiple-procedures success defined as the following up to 12 months following the index ablation procedure:
Absence of atrial arrhythmia recurrence on any type of recording ((= 30 sec by TTM (event monitor), Holters, 12-lead ECGs, rhythm strip or other diagnostic ECG documentation),
Absence of use of class I or III AAD (except for non-atrial arrhythmia)
1 year
Secondary health-related quality of life: Health-related quality of life will be evaluated using the SF-12 questionnaire. The SF-12 includes 8 concepts commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health. Results are expressed in terms of two meta-scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). High score indicates better functioning 6 months, 1 year
Secondary AF-specific quality of life Improvement in AF-specific quality of life will be assessed using QualiTy-of-life (AFEQT) questionnaire. Scores range from 0 to 100. A score of 0 corresponds to complete disability (or responding "extremely" limited, difficult or bothersome to all questions answered), while a score of 100 corresponds to no disability (or responding "not at all" limited, difficult or bothersome to all questions answered) 6 months, 1 year
Secondary Death Proportion of participants with death 7 days, 1 year
Secondary Stroke Proportion of participants with 7 days, 1 year
Secondary Embolic events from arrhythmia, Proportion of participants with embolic events from arrhythmia 1 year
Secondary Myocardial infarction Proportion of participants with Myocardial infarction 7 days
Secondary Persistent diaphragmatic paralysis Proportion of participants with Persistent diaphragmatic paralysis 7 days
Secondary Transient ischemic attack (TIA) Proportion of participants with Transient ischemic attack (TIA) 7 days
Secondary Peripheral or organ thromboembolism Proportion of participants with Peripheral or organ thromboembolism 7 days
Secondary Cardiac Tamponade / Perforation Proportion of participants with Cardiac Tamponade / Perforation 7 days
Secondary Pericarditis Proportion of participants with Pericarditis 7 days
Secondary Hospitalisation Proportion of participants with Hospitalisation (initial or prolonged), excluding hospitalisation solely due to arrhythmia recurrence 7 days
Secondary Heart block Proportion of participants with Heart block 7 days
Secondary Vascular access complications Proportion of participants with Vascular access complications 7 days
Secondary Pulmonary vein stenosis (PVS) Proportion of participants with Pulmonary vein stenosis (PVS) 1 year
Secondary Atrio-oesophageal fistula Proportion of participants with Atrio-oesophageal fistula 1 year
Secondary Total ablation procedure duration Index Ablation Procedure parameters: Total ablation procedure duration (in minutes), skin to skin Baseline
Secondary Left atrial (LA) dwell time during ablation procedure Index Ablation Procedure parameters: Left atrial (LA) dwell time, defined as the time (in minutes) transpiring from catheter entry to exit from the LA Baseline
Secondary Total fluoroscopy time during ablation procedure Index Ablation Procedure parameters: Total fluoroscopy time (in minutes), skin-to-skin Baseline
Secondary PV diameter Change in mean PV diameter 2 months 2 months
Secondary Incidence of acute vagal response during PVI Incidence of acute vagal response during PVI Baseline
Secondary mean heart rate Change in mean heart rate 1 year
Secondary heart rate variability Change in heart rate variability 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A